These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 22710898)

  • 1. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.
    Shah BD; Martin P; Sotomayor EM
    Cancer Control; 2012 Jul; 19(3):227-35. PubMed ID: 22710898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
    Dreyling M; Aurer I; Cortelazzo S; Hermine O; Hess G; Jerkeman M; Le Gouill S; Ribrag V; Trněný M; Visco C; Walewski J; Zaja F; Zinzani PL
    Leuk Lymphoma; 2018 Aug; 59(8):1814-1828. PubMed ID: 29172868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies in mantle cell lymphoma.
    Maddocks K; Blum KA
    Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current treatment strategy in mantle cell lymphoma].
    Ogura M
    Nihon Rinsho; 2014 Mar; 72(3):499-511. PubMed ID: 24724411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
    Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
    Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
    Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
    Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for mantle cell lymphoma.
    Smolewski P; Witkowska M; Robak T
    Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Till BG
    Curr Treat Options Oncol; 2018 Jul; 19(9):45. PubMed ID: 30032463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
    Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.
    Cohen JB; Zain JM; Kahl BS
    Am Soc Clin Oncol Educ Book; 2017; 37():512-525. PubMed ID: 28561694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
    Navarro Matilla B; García-Marco JA
    Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
    Nazeef M; Kahl BS
    Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.
    Aurer I
    Curr Opin Oncol; 2019 Sep; 31(5):374-379. PubMed ID: 31233483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.